3,660 Shares in ICU Medical, Inc. $ICUI Bought by Verdence Capital Advisors LLC

Key Points

• Verdence Capital Advisors LLC bought 3,660 shares of ICU Medical, valued at approximately $484,000, marking a continued interest from institutional investors in the company.
• Several analyst reports have altered their ratings on ICU Medical, with Piper Sandler raising the target price to $153 and Wall Street Zen upgrading the stock from a hold to a buy rating.
• Recent insider trading includes CEO Vivek Jain purchasing 21,929 shares, indicating confidence in the company’s future prospects.

Verdence Capital Advisors LLC purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,660 shares of the medical instruments supplier's stock, valued at approximately $484,000.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC increased its position in ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after buying an additional 153 shares in the last quarter. Blue Trust Inc. increased its position in ICU Medical by 23.0% during the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after buying an additional 150 shares in the last quarter. United Services Automobile Association purchased a new position in ICU Medical during the first quarter worth $218,000. Johnson Investment Counsel Inc. raised its position in shares of ICU Medical by 17.7% in the second quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier's stock valued at $225,000 after buying an additional 256 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in shares of ICU Medical during the first quarter valued at approximately $235,000. Hedge funds and other institutional investors own 96.10% of the company's stock.

Analyst Upgrades and Downgrades

ICUI has been the topic of a number of analyst reports. Piper Sandler raised their target price on shares of ICU Medical from $145.00 to $153.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 10th. Wall Street Zen upgraded ICU Medical from a "hold" rating to a "buy" rating in a report on Friday, September 5th. Raymond James Financial lowered their price objective on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research report on Friday, August 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ICU Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $181.00.

Insiders Place Their Bets

In related news, Director David C. Greenberg acquired 1,200 shares of the business's stock in a transaction on Wednesday, August 27th. The shares were bought at an average cost of $126.42 per share, with a total value of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares of the company's stock, valued at $1,006,303.20. This trade represents a 17.75% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain bought 21,929 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was bought at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the transaction, the chief executive officer directly owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company's stock.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $116.29 on Thursday. The business has a 50-day moving average of $123.61 and a two-hundred day moving average of $130.35. The firm has a market capitalization of $2.87 billion, a PE ratio of -76.51 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The business had revenue of $543.57 million during the quarter, compared to analysts' expectations of $543.33 million. During the same quarter in the previous year, the business earned $1.56 EPS. The company's revenue for the quarter was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, research analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.